Published in Biochim Biophys Acta on September 13, 1974
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation (1996) 2.72
Complete covalent structure of human beta-thromboglobulin. Biochemistry (1978) 2.64
The identification of fibrinopeptide B as a chemotactic agent derived from human fibrinogen. Br J Haematol (1974) 1.70
High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med (2000) 1.60
Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res (1981) 1.54
Haemoglobin Hammersmith (beta-42 (CDI) Phe replaced by ser). Nature (1967) 1.52
The isolation and characterisation of a platelet-specific beta-globulin (beta-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochim Biophys Acta (1975) 1.37
The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res (1975) 1.31
The sulphite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products. Clin Chim Acta (1976) 1.18
The sialic acids of horse serum with special reference to their virus inhibitory properties. Biochim Biophys Acta (1968) 1.17
The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J (1980) 1.13
Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies. Thromb Haemost (1996) 1.13
Platelet antiheparin activity. The isolation and characterisation of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound antiheparin activity. Biochim Biophys Acta (1975) 1.13
Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res (1987) 1.12
The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4. Thromb Res (1978) 1.11
Chromatography of human prothrombin complex or dextran sulphate agarose. Thromb Res (1977) 1.09
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) (2007) 1.08
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol (1976) 1.04
Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Acad Radiol (1998) 1.03
Generation of chemotactic activity for leukocytes by the action of thrombin on human fibrinogen. Nat New Biol (1973) 1.00
Three approaches to the radioimmunoassay of human beta-thromboglobulin. Br J Haematol (1976) 0.99
Reductive amination for solid-phase coupling of protein. A practical alternative to cyanogen bromide. J Immunol Methods (1986) 0.99
Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. Biochim Biophys Acta (1973) 0.99
Isolation of a macroglycopeptide from human platelets. Biochemistry (1970) 0.99
The isolation and properties of gamma inhibitor: an equine alpha 2-macroglobulin sub-fraction. Biochim Biophys Acta (1968) 0.98
Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry (1991) 0.97
A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost (1985) 0.97
The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemost (1986) 0.96
Lymphocyte, granulocyte and platelet contamination of blood frozen by the low-glycerol liquid nitrogen technique. Br J Haematol (1980) 0.96
In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am (1998) 0.96
The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction. Thromb Res (1983) 0.96
A radioimmunoassay for platelet factor 4. Thromb Res (1976) 0.95
Fibrin crosslinks and lysis rates. Thromb Res (1979) 0.94
Plasminogen activators in human colorectal neoplasia. Br Med J (Clin Res Ed) (1986) 0.94
Problems in the assay of thrombin using synthetic peptides as substrates. Thromb Res (1977) 0.93
The in vivo release of human platelet factor 4 by heparin. Thromb Res (1982) 0.93
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. Blood Coagul Fibrinolysis (2000) 0.93
The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg (1998) 0.92
Studies on glycoproteins. 3. Isolation of sialylglycopeptides from human platelet membranes. Biochemistry (1969) 0.91
High-frequency ultrasonic detection of thrombi with a targeted contrast system. Ultrasound Med Biol (1997) 0.90
Unreliability of current serum fibrin degradation product (FDP) assays. Thromb Haemost (1985) 0.90
Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent. J Acoust Soc Am (2000) 0.90
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? Gut (1987) 0.90
The absorption, clearance and metabolic fate of dermatan sulphate administered to man--studies using a radioiodinated derivative. Thromb Haemost (1989) 0.90
A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb Res (1983) 0.89
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. J Vasc Surg (1995) 0.89
The generation of chemotactic activity for human leukocytes by the action of plasmin on human fibrinogen. Thromb Res (1975) 0.89
Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies. Thromb Haemost (1985) 0.89
Monoclonal antibodies to human fibrin: interaction with other animal fibrins. Thromb Haemost (1996) 0.89
Human platelet factor 4 and tissue mast cells. Thromb Res (1981) 0.88
The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemost (1985) 0.88
An international collaborative study to investigate standardisation of hirudin potency. Thromb Haemost (1993) 0.88
The binding of purified factor VIII/von Willebrand factor to collagens of differing type and form. Thromb Res (1982) 0.87
The different forms of antithrombin II in serum. Thromb Haemost (1977) 0.87
Tandem purification of mouse IgM monoclonal antibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography. J Chromatogr (1986) 0.86
Isolation and properties of human vascular plasminogen activator. Thromb Haemost (1981) 0.86
Quantitation by radioimmunoassay of thrombospondin synthesised and secreted by human endothelial cells. Thromb Haemost (1984) 0.85
Neutralization of heparin in plasma by platelet factor 4 and protamine sulphate. Br J Haematol (1978) 0.85
The rapid fibrin plate - a method for plasminogen activator assay. Thromb Haemost (1977) 0.85
Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res (1986) 0.85
The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Br J Haematol (1993) 0.85
A comparison of methods for platelet lysis and the isolation of platelet membranes. Thromb Diath Haemorrh (1971) 0.85
Plasma and serum antithrombin - III: differentiation by crossed immunoelectrophoresis. Thromb Res (1975) 0.84
Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost (1992) 0.84
A chromatographic procedure for the purification of influenza virus. J Gen Virol (1967) 0.84
Immunoaffinity purification of factor VIII complex. Thromb Haemost (1987) 0.84
A collaborative study to establish the 2nd International Standard for Fibrinogen, Plasma. Thromb Haemost (2000) 0.84
Monoclonal antibodies directed against human alpha-thrombin and the thrombin-antithrombin III complex. Thromb Res (1984) 0.84
A performance evaluation of commercial fibrinogen reference preparations and assays for Clauss and PT-derived fibrinogen. Thromb Haemost (2002) 0.84
Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest. Thromb Diath Haemorrh (1975) 0.83
The ability of fibrinogen fragments to support ADP-induced platelet aggregation. Thromb Res (1979) 0.83
Standard for human thrombin. Thromb Diath Haemorrh (1975) 0.83
Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. Biochemistry (1988) 0.83
Fibrin subunits in venous and arterial thromboembolism. Cardiovasc Res (1976) 0.83
Plasma beta-thromboglobulin in diabetes mellitus. Diabetes (1977) 0.83
Isolation of a glycoprotein fraction from human platelet membranes which inhibits viral haemagglutination. Nature (1968) 0.83
The transfer of platelet factor 4 from its proteoglycan carrier to natural and synthetic polymers. Biochim Biophys Acta (1981) 0.83
Generation and partial characterization of five monoclonal antibodies with high affinities for fibrin. Blood Coagul Fibrinolysis (1993) 0.82
Unreliability of chromogenic substrates for assay of the clotting activity of thrombin. Haemostasis (1978) 0.82
Immunological localisation of beta-thromboglobulin and platelet factor 4 in human megakaryocytes and platelets. J Clin Pathol (1982) 0.82
Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. J Biol Chem (1992) 0.82
Preparation and stability of a highly purified human thrombin standard. Thromb Res (1980) 0.82
Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta (1975) 0.82
Low-resolution structure of the complex of human blood platelet factor 4 with heparin determined by small-angle neutron scattering. Biochim Biophys Acta (1986) 0.82
Temperature dependence of ultrasonic enhancement with a site-targeted contrast agent. J Acoust Soc Am (2001) 0.82
A sensitive competitive binding assay for exogenous and endogenous heparins. Thromb Res (1982) 0.81
High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. Thromb Res (1997) 0.81
Localisation of carbohydrate in the subunits of human fibinogen and its plasmin induced fragments. Biochim Biophys Acta (1972) 0.81
Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. Eur J Biochem (1986) 0.81
The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system--a human volunteer and experimental animal study. Thromb Haemost (1985) 0.81
Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol (1992) 0.81
Protein modification during antiviral heat bioprocessing. Biotechnol Bioeng (2000) 0.81
Human serum cholinesterase. I. Partial purification andnature of the heterogeneity of this system. Biochim Biophys Acta (1970) 0.81
Plasma fibrinogen and its fragments during streptokinase treatment. Br J Haematol (1974) 0.81
Metabolism of sodium pentosan polysulphate in man--catabolism of iodinated derivatives. Thromb Haemost (1984) 0.81
Identification of D dimer-E complex in disseminated intravascular coagulation. Thromb Res (1980) 0.81
Structure of fibrinogen and degradation products of fibrinogen and fibrin. Br Med Bull (1977) 0.80
Immunomodulatory properties of platelet factor 4: prevention of concanavalin A suppressor-induction in vitro and augmentation of an antigen-specific delayed-type hypersensitivity response in vivo. Immunology (1990) 0.80